Drug Trial Radar · NCT04902872
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
69
Actual
Start
May 3, 2021
Primary completion
Jun 24, 2025
Study completion Jun 24, 2025
Sponsor
- Lead sponsor
- Cybrexa TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
Conditions
- Solid Tumor, Adult
- Epithelial Ovarian Cancer
- Small Cell Lung Carcinoma
- Breast Cancer
- Colorectal Cancer
- Pancreas Cancer
- Appendix Cancer
- Non-small Cell Lung Cancer
- Gastric Cancer
- Esophagus Cancer
- Urothelial Carcinoma
- Sarcoma
Interventions
CBX-12Drug
CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Incidence of treatment-emergent adverse events (TEAEs)Time frame: Through the end of study, estimated as 6 months
- Phase 1: Recommended Phase 2 Dose for Daily x 3 every 3 weeks schedule of CBX-12 (Schedule B)Time frame: 15 months
- Phase 1: Recommended Phase 2 Dose for Once Weekly schedule of CBX-12 (Schedule C)Time frame: 15 months
- Phase 1: Recommended Phase 2 Dose for Once Every 3 Weeks schedule of CBX-12 (Modified Schedule B)Time frame: 15 months
- Phase 2: Overall response rate (ORR)Time frame: Through the end of study, estimated as 6 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Yale Cancer Center
New Haven, Connecticut
NEXT Oncology
Austin, Texas
MD Anderson Cancer Center
Houston, Texas
NEXT Oncology
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.